Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration- resistant prostate cancer and bone metastases

Abstract

Radium-223 dichloride (223Ra) (Sofigo), a calcium-mimetic agent that specifically targets bone lesions, was approved in 2020 by China Food and Drug Administration (CFDA) to treat castration‑resistant prostate cancer and bone metastases (CRPC) with symptomatic bone metastases and no known visceral metastatic diseases. It is the fisrt α particles targeted radiopharmaceutical therapeutic drugs in the world to be applied to CRPC with bone metastase (mCRPC) patients. In recent years, the application of nuclear medicine technology to evaluate the efficacy of 223Ra in the treatment of mCRPC patients abroad has been very common, but only few hospitals in China have entered the stage of clinical application. In order to provide clear recommendations for clinical applications of radionuclide imaging in evaluating the efficacy of 223Ra in the treatment of mCRPC, a survey of recent progress is carried out in this study, and public available clinical data of single photon emission computed tomography/computed tomography (SPECT/CT), and positron emission tomography/computed tomography (PET/CT) using radiolabeled chemical agents worldwide in the evaluation of 223Ra treatment for patients with CRPC and bone metastase,are presented and commented.

Keywords

• 223ra
• mcrpc
• spect/ct
• pet/ct